Long-term Effect of Sodium Oxybate (Xyrem®) in Spasmodic Dysphonia with Vocal Tremor

Kristina Simonyan, Steven J Frucht, Kristina Simonyan, Steven J Frucht

Abstract

Background: Symptoms of spasmodic dysphonia (SD) are usually managed successfully with botulinum toxin injections. Vocal tremor (VT), which accompanies SD, has a poor response to this treatment.

Case report: We report a case of a female with SD and VT who became symptom-free for 10 months after the intake of a single dose of sodium oxybate (Xyrem®). The long-term treatment effect correlated with attenuated brain activity in the key regions of dystonic brain network.

Discussion: Our case demonstrates that the novel treatment of sodium oxybate may hold promise for SD patients, especially those who have associated VT.

Keywords: Focal dystonia; brain modulation; treatment.

Conflict of interest statement

Conflict of Interests: The authors report no conflict of interest.

Figures

Figure 1. Brain Activity During Production of…
Figure 1. Brain Activity During Production of English Sentences Containing a Large Number of Vowels.
Before treatment with sodium oxybate (A), 90 minutes after treatment (B), and 8 months after treatment (C). Brain activity is shown on the inflated brain surfaces in the standard Talairach–Tournoux space and on the series of axial slices. The color bar represents t score.

References

    1. Sulica L, Louis ED. Clinical characteristics of essential voice tremor: a study of 34 cases. Laryngoscope. 2010;120:516–528. doi: 10.1002/lary.20702.
    1. Gurey LE, Sinclair CF, Blitzer A. A new paradigm for the management of essential vocal tremor with botulinum toxin. Laryngoscope. 2013;123:2497–2501.
    1. Brin MF, Blitzer A, Stewart C. Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin. Adv Neurol. 1998;78:237–252.
    1. Ludlow CL, Adler CH, Berke GS, et al. Research priorities in spasmodic dysphonia. Otolaryngol Head Neck Surg. 2008;139:495–505. doi: 10.1016/j.otohns.2008.05.624.
    1. Simonyan K, Ludlow CL. Abnormal activation of the primary somatosensory cortex in spasmodic dysphonia: an fMRI study. Cereb Cortex. 2010;20:2749–2759. doi: 10.1093/cercor/bhq023.
    1. Ali SO, Thomassen M, Schulz GM, et al. Alterations in CNS activity induced by botulinum toxin treatment in spasmodic dysphonia: an H215O PET study. J Speech Lang Hear Res. 2006;49:1127–1146. doi: 10.1044/1092-4388(2006/081).
    1. Frucht SJ, Bordelon Y, Houghton WH, Reardan D. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord. 2005;20:1330–1337. doi: 10.1002/mds.20605.
    1. Frucht SJ, Houghton WC, Bordelon Y, Greene PE, Louis ED. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology. 2005;65:1967–1969. doi: 10.1212/.
    1. Crunelli V, Ernri Z, Leresche N. Unravelling the brain targets of gamma-hydroxybutyric acid. Curr Opin Pharmacol. 2006;6:44–52. doi: 10.1016/j.coph.2005.10.001.
    1. Levy LM, Ziemann U, Chen R, Cohen LG. Rapid modulation of GABA in sensorimotor cortex induced by acute deafferentation. Ann Neurol. 2002;52:755–761. doi: 10.1002/ana.10372.
    1. Marjanska M, Lehericy S, Valabregue R, et al. Brain dynamic neurochemical changes in dystonic patients: a magnetic resonance spectroscopy study. Movement Disord. 2013;28:201–209. doi: 10.1002/mds.25279.
    1. Hallett M. Neurophysiology of dystonia: the role of inhibition. Neurobiol Dis. 2011;42:177–184. doi: 10.1016/j.nbd.2010.08.025.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever